271 related articles for article (PubMed ID: 32929351)
1. PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia.
Li K; Wang F; Yang ZN; Cui B; Li PP; Li ZY; Hu ZW; Zhu HH
Theranostics; 2020; 10(22):10326-10340. PubMed ID: 32929351
[TBL] [Abstract][Full Text] [Related]
2. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
3. Expression of PML-RARα is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia.
Zhu HH; Qin YZ; Lai YY; Shi HX; Liu YR; Jiang B; Huang XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):872-8. PubMed ID: 23998577
[TBL] [Abstract][Full Text] [Related]
4. TRIB3 Stabilizes High TWIST1 Expression to Promote Rapid APL Progression and ATRA Resistance.
Lin J; Zhang W; Niu LT; Zhu YM; Weng XQ; Sheng Y; Zhu J; Xu J
Clin Cancer Res; 2019 Oct; 25(20):6228-6242. PubMed ID: 31235507
[TBL] [Abstract][Full Text] [Related]
5. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia.
Guidez F; Ivins S; Zhu J; Söderström M; Waxman S; Zelent A
Blood; 1998 Apr; 91(8):2634-42. PubMed ID: 9531570
[TBL] [Abstract][Full Text] [Related]
6. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
Kitareewan S; Pitha-Rowe I; Sekula D; Lowrey CH; Nemeth MJ; Golub TR; Freemantle SJ; Dmitrovsky E
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3806-11. PubMed ID: 11891284
[TBL] [Abstract][Full Text] [Related]
7. Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation.
Yang S; Jeong JH; Brown AL; Lee CH; Pandolfi PP; Chung JH; Kim MK
J Biol Chem; 2006 Sep; 281(36):26645-54. PubMed ID: 16835227
[TBL] [Abstract][Full Text] [Related]
8. Blockade of deubiquitinase YOD1 degrades oncogenic PML/RAR
Shao X; Chen Y; Wang W; Du W; Zhang X; Cai M; Bing S; Cao J; Xu X; Yang B; He Q; Ying M
Acta Pharm Sin B; 2022 Apr; 12(4):1856-1870. PubMed ID: 35847510
[TBL] [Abstract][Full Text] [Related]
9. Skp2 promotes APL progression through the stabilization of oncoprotein PML-RARα and the inhibition of JunB expression.
Dan W; Zhong L; Yu L; Xiong L; Li J; Ye J; Luo X; Liu C; Chu X; Liu B
Life Sci; 2022 Jan; 289():120231. PubMed ID: 34921867
[TBL] [Abstract][Full Text] [Related]
10. Activation of
Zhang F; Zhu YL; Deng WL; Zhu J; Zhang J
J Leukoc Biol; 2017 Mar; 101(3):655-664. PubMed ID: 27605212
[TBL] [Abstract][Full Text] [Related]
11. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Tsao T; Konoplev S; Shi Y; Ling X; Watt JC; Tsutsumi-Ishii Y; Ohsaka A; Nagaoka I; Issa JP; Kogan SC; Andreeff M
Cancer Biol Ther; 2007 Dec; 6(12):1967-77. PubMed ID: 18075297
[TBL] [Abstract][Full Text] [Related]
12. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
[TBL] [Abstract][Full Text] [Related]
13. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
14. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
15. The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
Jing Y; Xia L; Lu M; Waxman S
Oncogene; 2003 Jun; 22(26):4083-91. PubMed ID: 12821942
[TBL] [Abstract][Full Text] [Related]
16. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
Duprez E; Lillehaug JR; Gaub MP; Lanotte M
Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
[TBL] [Abstract][Full Text] [Related]
17. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
18. S100A3 a partner protein regulating the stability/activity of RARα and PML-RARα in cellular models of breast/lung cancer and acute myeloid leukemia.
Gianni M; Terao M; Kurosaki M; Paroni G; Brunelli L; Pastorelli R; Zanetti A; Lupi M; Acquavita A; Bolis M; Fratelli M; Rochette-Egly C; Garattini E
Oncogene; 2019 Apr; 38(14):2482-2500. PubMed ID: 30532072
[TBL] [Abstract][Full Text] [Related]
19. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
[TBL] [Abstract][Full Text] [Related]
20. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]